◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ACAD

ACADIA Pharmaceuticals Inc (ACAD) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-22

ACADIA Pharmaceuticals Inc (ACAD) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 796 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, ACAD reported $1.1B in revenue and $391M in net income.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Interactive charts & full statements → Open the ACAD valuation workbench →

ACAD Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$1.1B	$1.1B	$958M	$726M	$517M	$484M	$442M	$339M	$224M	$125M	$17M	$0M	$0M	$1M	$5M	$2M	$42M	$6M	$2M	$8M	$8M
Gross Profit	$1.0B	$983M	$876M	$681M	$507M	$465M	$421M	$319M	$205M	$112M	$13M	$0M	$0M	($26M)	$5M	$2M	$42M	$6M	$2M	$8M	$8M
Gross Margin %	91.1%	91.7%	91.5%	93.7%	98.0%	96.0%	95.3%	94.2%	91.8%	89.5%	74.6%	100.0%	100.0%	-2233.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$86M	$105M	$231M	($73M)	($224M)	($170M)	($287M)	($247M)	($247M)	($292M)	($273M)	($165M)	($93M)	($38M)	($21M)	($23M)	$15M	($45M)	($67M)	($63M)	($49M)
Operating Margin %	7.6%	9.8%	24.1%	-10.1%	-43.2%	-35.2%	-64.9%	-72.7%	-110.6%	-234.1%	-1574.1%	-269855.7%	-77691.7%	-3344.7%	-425.6%	-1105.6%	35.8%	-710.6%	-4212.4%	-829.3%	-603.1%
Net Income	$380M	$391M	$226M	($61M)	($216M)	($168M)	($282M)	($235M)	($245M)	($289M)	($271M)	($164M)	($92M)	($38M)	($21M)	($23M)	$15M	($45M)	($64M)	($56M)	($45M)
Net Margin %	33.4%	36.5%	23.6%	-8.4%	-41.8%	-34.7%	-63.7%	-69.4%	-109.6%	-231.7%	-1565.9%	-269578.7%	-77062.5%	-3314.2%	-424.9%	-1101.4%	35.9%	-705.5%	-4040.5%	-746.4%	-553.9%
EBITDA	$116M	$151M	$100M	($45M)	($222M)	($167M)	($284M)	($244M)	($244M)	($290M)	($271M)	($164M)	($93M)	($38M)	($21M)	($22M)	$16M	($44M)	($66M)	($63M)	($49M)
Earnings Per Share (EPS)	$2.22	$2.28	$1.36	$-0.37	$-1.34	$-1.05	$-1.79	$-1.60	$-1.94	$-2.36	$-2.34	$-1.63	$-0.95	$-0.44	$-0.38	$-0.44	$0.39	$-1.20	$-1.73	$-1.60	$-1.61
Shares Outstanding (M)	173M	171M	166M	164M	162M	160M	157M	147M	127M	123M	116M	101M	97M	86M	55M	52M	39M	37M	37M	35M	28M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACAD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$308M	$268M	$284M	$279M	$265M	$244M	$260M	$250M
Gross Profit	$280M	$243M	$258M	$257M	$244M	$224M	$238M	$232M
Gross Margin %	90.8%	90.8%	90.8%	92.2%	92.2%	91.6%	91.6%	92.5%
Operating Income (EBIT)	$38M	($5M)	$17M	$36M	$32M	$19M	$154M	$32M
Operating Margin %	12.3%	-1.7%	6.1%	12.8%	12.2%	7.9%	59.1%	12.6%
Net Income	$32M	$4M	$274M	$72M	$27M	$19M	$144M	$33M
Net Margin %	10.2%	1.4%	96.3%	25.8%	10.1%	7.8%	55.4%	13.1%
EBITDA	$32M	$7M	$29M	$48M	$43M	$31M	$12M	$41M
Earnings Per Share (EPS)	$0.18	$0.02	$1.60	$0.42	$0.16	$0.11	$0.86	$0.20
Shares Outstanding (M)	173M	173M	171M	171M	169M	168M	166M	166M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACAD Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$194M	$110M	$158M	$17M	($114M)	($126M)	($136M)	($151M)	($167M)	($218M)	($210M)	($122M)	($66M)	($32M)	($22M)	($20M)	($11M)	($14M)	($65M)	($55M)	($41M)
Capital Expenditures (CapEx)	$20M	$5M	$1M	$40M	$0M	$1M	$8M	$1M	$2M	$1M	$10M	$2M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$2M
Free Cash Flow (FCF)	$174M	$105M	$157M	($23M)	($114M)	($127M)	($144M)	($152M)	($170M)	($219M)	($220M)	($124M)	($67M)	($32M)	($22M)	($20M)	($11M)	($14M)	($65M)	($55M)	($43M)
FCF Margin %	15.3%	9.8%	16.4%	-3.2%	-22.1%	-26.2%	-32.5%	-44.9%	-75.8%	-175.1%	-1268.9%	-203173.8%	-55511.7%	-2828.6%	-440.9%	-962.8%	-25.4%	-215.2%	-4094.0%	-732.5%	-534.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACAD Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$135M	$34M	($49M)	$74M	$64M	$20M	$40M	$63M
Capital Expenditures (CapEx)	$10M	$5M	$4M	$0M	$99M	$99M	$0M	$0M
Free Cash Flow (FCF)	$124M	$29M	($53M)	$74M	($35M)	($79M)	$40M	$63M
FCF Margin %	40.4%	10.7%	-18.6%	26.5%	-13.1%	-32.1%	15.4%	25.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACAD Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.7B	$1.6B	$1.2B	$749M	$588M	$700M	$783M	$783M	$540M	$385M	$561M	$222M	$325M	$189M	$109M	$32M	$38M	$50M	$65M	$135M	$90M
Cash & Cash Equivalents	$385M	$178M	$320M	$189M	$115M	$147M	$326M	$190M	$135M	$69M	$164M	$102M	$62M	$12M	$58M	$7M	$7M	$18M	$21M	$17M	$15M
Total Liabilities	$436M	$337M	$455M	$317M	$187M	$159M	$156M	$84M	$61M	$49M	$43M	$22M	$16M	$7M	$24M	$9M	$9M	$38M	$12M	$21M	$22M
Total Debt (Short + Long-Term)	$14M	$12M	$10M	$9M	$9M	$8M	$5M	$3M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$2M	$2M
Total Shareholders' Equity	$1.3B	$1.2B	$733M	$432M	$400M	$541M	$627M	$699M	$479M	$335M	$518M	$200M	$309M	$182M	$85M	$23M	$30M	$12M	$53M	$114M	$67M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACAD viewer.

Other Companies in BIOTECHNOLOGY

DFTX · Definium Therapeutics, Inc. — $5 billion
ERAS · Erasca Inc — $5 billion
PBLS · Parabilis Medicines, Inc. Common Stock — $5 billion
EWTX · Edgewise Therapeutics Inc — $5 billion
IOVA · Iovance Biotherapeutics Inc — $5 billion
MANE · Veradermics, Incorporated — $4 billion
TLX · Telix Pharmaceuticals Limited — $4 billion
RLAY · Relay Therapeutics Inc — $4 billion

← ACAA All “A” companies ACAN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.